Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo
Surufatinib (1 RCT; 172 participants)
Estimates of effects, ranking, and certainty of evidence for… leads to lower surufatinib (1 RCT; 172 participants) compared with placebo (high certainty).
2 findings from 1 review
- Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyHR 0.49 [0.32, 0.76]1 study · 172 participantsHigh
- Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyOR 1.99 [1.02, 3.88]1 study · 172 participantsHigh